Clinical Trial Update: Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update evaluates the combination of talimogene laherparepvec (T-VEC) and nivolumab for patients with refractory lymphomas or advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Basal Cell Carcinoma
• Extramammary Paget Disease
• Merkel Cell Carcinoma
• Mycosis Fungoides
• Sezary Syndrome
• Squamous Cell Carcinoma of the Skin

Drugs mentioned

• Imlygic (Talimogene laherparepvec)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Status: ACTIVE_NOT_RECRUITING